Editas Medicine (EDIT)
(Real Time Quote from BATS)
$3.94 USD
-0.06 (-1.50%)
Updated Aug 16, 2024 12:54 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
EDIT 3.94 -0.06(-1.50%)
Will EDIT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EDIT
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Illumina (ILMN) Q2 Earnings and Revenues Top Estimates
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Other News for EDIT
Editas Medicine Hold Rating with Revised Price Target Amidst Mixed Financial Signals
Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline
Morgan Stanley Keeps Their Hold Rating on Editas Medicine (EDIT)
Evercore ISI Remains a Hold on Editas Medicine (EDIT)
Editas Medicine (EDIT) Gets a Buy from Truist Financial